pISSN 1226-6051
eISSN 2508-786X

Table. 5.

Table. 5.

Risk Factor Analysis for PD-1 inhibitors therapy associated thyroid-related adverse events

Unadjusted HR1 (95% CI) Adjusted HR2 (95 % CI)
Age, yr
<50 Reference Reference
50-59 1.951 (0.705-5.403) 1.874 (0.655-5.361)
60-69 1.176 (0.445-3.109) 1.118 (0.402-3.107)
≥70 1.662 (0.622-4.439) 1.573 (0.560-4.417)
Gender
Male Reference Reference
Female 0.910 (0.474-1.748) 0.983 (0.501-1.931)
BMI, kg/m2
<18.5 Reference Reference
18.5-24.9 0.639 (0.217-1.884) 0.726 (0.238-2.218)
≥25 1.163 (0.390-3.467) 1.397 (0.449-4.346)
Medication
Pembrolizumab Reference Reference
Nivolumab 0.817 (0.448-1.489) 0.588 (0.313-1.106)
ECOG PS
0 Reference Reference
1 2.936 (0.402-21.420) 3.311 (0.440-24.938)
2 1.026 (0.064-16.521) 1.137 (0.067-19.203)

HR, Hazard ratio; CI, confidence interval; BMI, body mass index; ECOG PS, Eastern Cooperative Oncology Group

*indicates P<0.05

Korean J Clin Pharm 2021;31:188-97 https://doi.org/10.24304/kjcp.2021.31.3.188
© 2021 Korean J Clin Pharm